BOSTON (Reuters) - Vertex Pharmaceuticals Inc said on Tuesday it will discontinue development of an experimental drug to treat hepatitis C after it failed to show sufficient efficacy. The company, which was developing the oral drug, known as ALS-2158, with partner Alios BioPharma Inc, said it will continue development of another hepatitis C drug, ALS-2200, after it showed promise in an early trial. Shares of Vertex were down 3.4 percent at $56.75. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment